News Quantified

ITCI – intra-cellular therapies inc. (US:NASDAQ)

Stock Stats

News Stats

Order Stats

News

Intra-Cellular Therapies, Inc. (NASDAQ: ITCI) had its "neutral" rating re-affirmed by analysts at Cantor Fitzgerald. They now have a $132.00 price target on the stock.

Johnson & Johnson Announces Expected Closing Date for Intra-Cellular Acquisition [Yahoo! Finance]

Intra-Cellular Therapies, Inc. (NASDAQ: ITCI) is now covered by analysts at StockNews.com. They set a "hold" rating on the stock.

Jefferies profit misses estimates as bond trading, equity underwriting weaken [Yahoo! Finance]

Jefferies profit falls on weaker bond trading, equity underwriting [Yahoo! Finance Canada]

9.6%

MISS

-5.8%

BEAT

-2.9%

BEAT

Cantor Fitzgerald

Cantor Fitzgerald

Form 4 Intra-Cellular Therapies For: Apr 02 Filed by: Salas Eduardo Rene

Form 4 Intra-Cellular Therapies For: Apr 02 Filed by: RIGGS RORY B

Form 4 Intra-Cellular Therapies For: Apr 02 Filed by: Halstead Michael

Form 4 Intra-Cellular Therapies For: Apr 02 Filed by: VAN NOSTRAND ROBERT L

Form 4 Intra-Cellular Therapies For: Apr 02 Filed by: Neumann Mark

Top News Gainers

12/23 FDA Approves Intra-Cellular Therapies’ Novel Antipsychotic, CAPLYTA® (lumateperone) for the Treatment of Schizophrenia in Adults 194.7%

6/13 Intra-Cellular Therapies Announces FDA Advisory Committee Meeting to Review the NDA for Lumateperone for the Treatment of Schizophrenia in Adults 14.3%

6/14 Form DEFA14A Intra-Cellular Therapies 13.1%

7/8 Intra-Cellular drug fails bipolar depression study; shares fall 14% [Reuters (UK)] 12.8%

4/7 Intra-Cellular Therapies: This Small Cap Biotech Will Not Be Small For Long [Seeking Alpha] 11.4%

8/5 Intra-Cellular Therapies to Host Conference Call to Provide Regulatory Update Following Recent Meeting with FDA 8.5%

4/29 Intra-Cellular Therapies to Host First Quarter 2020 Financial Results Conference Call and Webcast 7.4%

9/7 Intra-Cellular Therapies Inc (NASDAQ: ITCI) was upgraded by analysts at BidaskClub from a "strong sell" rating to a "sell" rating. 7.4%

1/6 Form S-3ASR Intra-Cellular Therapies 6.9%

10/15 Intra-Cellular Therapies Inc (NASDAQ: ITCI) was downgraded by analysts at Zacks Investment Research from a "strong-buy" rating to a "hold" rating. 5.8%

Top News Decliners

7/8 Intra-Cellular Therapies Announces Positive Top-line Results from a Phase 3 Trial of Lumateperone in Patients with Bipolar Depression -16.4%

12/23 Intra-Cellular drug approval augurs well for CNS stocks, Stifel says [Seeking Alpha] -14.1%

3/6 Intra-Cellular Therapies Inc (NASDAQ: ITCI) was downgraded by analysts at ValuEngine from a "hold" rating to a "sell" rating. -13.4%

1/7 Intra-Cellular Therapies Prices Public Offering of Common Stock -12.7%

3/18 Intra-Cellular Therapies Inc (NASDAQ: ITCI) was downgraded by analysts at BidaskClub from a "hold" rating to a "sell" rating. -8.7%

6/19 Form 4/A Intra-Cellular Therapies For: Nov 22 Filed by: Alafi Christopher D -8.4%

7/24 Form 8-K Intra-Cellular Therapies For: Jul 23 -8.2%

9/12 Form 424B3 Intra-Cellular Therapies -7.6%

2/21 Intra-Cellular Therapies Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) -6.9%

1/8 Form 4 Intra-Cellular Therapies For: Jan 06 Filed by: Hineline Lawrence J. -5.1%

Live Event: How Top Hedge Funds Use News To Make Money From The Stock Market & How Ordinary People Are Copying Their Strategies

If you could use the news to make money from the stock market, would you? Join us on our live online event where you’ll discover this simple scientific method that has allowed ordinary people get a huge return from the stock market without excessive risk.

Click Here To Register For The Live Online Workshop

In short, News Quantified specializes in matching financial news with market data. We've analyzed 10s of millions of news events and know exactly which ones have an outsized impact on stock prices. So every single time a news item is released we know exactly what the average effect will be on a particular stock.

Latest Posts

Trading the Google Earnings Announcement: A Strategic Preview

Earnings Week Wrap-up and Takeaways

Earnings Season: Q3 Review, Q4 Kickoff – Morgan Stanley, Bank of America, Goldman Sachs, Netflix

Guerrilla Learning Opportunity: Wealth365 Conference Featuring News Quantified Founder and Much More

The Smart Way to Ten Minutes Per Day